The in vitro results confirmed that TanCAR-T cells showed superior efficacy against tumor cells containing only the sole target antigen compared to monospecific CAR-T cells (i.e., anti-EGFRvIII CAR-T cells and anti-IL-13Rα2 CAR-T cells). This evidence concerns the gene IL13RA2 and neoplasm.